Senseonics Holdings (SENS) AI Stock Analysis

• Market Cap: $380.69M
• Dividend Yield: N/A
• Average Volume (3M): 5.05M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.80
• Revenue Growth: 1.64%
• EPS Growth: 16.02%
• Country: US
• Employees: 117
• Sector: Healthcare
• Sector Strength: 42
• Industry: Medical - Devices
• EPS (TTM): -0.02
• Shares Outstanding: 754,291,100
• 10 Day Avg. Volume: 9,385,109
• 30 Day Avg. Volume: 5,045,646
• PEG Ratio: N/A
• Price to Book (P/B): -21.88
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -6.07
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $1.70
• Price Target Upside: 240.00% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 6

• Rating: 50 Neutral
• Price Target: $0.50 ▲( 0.00% Upside)

Senseonics Holdings shows promise with revenue growth and strategic partnerships, but is hindered by negative profitability, high debt, and valuation challenges. The earnings call provided a positive outlook, yet operational and financial risks remain significant.

Positive Factors

Market Expansion

Physicians captured in our sample set expect the US CGM category to expand 20%+ over the next two years, which is ahead of the estimated combined +17-18% forecast from market leaders Abbott Laboratories and Dexcom.

Product Competitiveness

The company's Eversense 365 platform is the only FDA-approved implantable CGM that is cleared for continuous blood glucose monitoring for 12 months, which compares to an average of 10-14 days for competing platforms that are worn externally.

Strategic Partnerships

The partnership with Ascensia Diabetes Care now markets E365 to more than 2,400 annual prescribers, with the majority being new prescribers.

Negative Factors

Financial Concerns

SENS shares are considered expensive as they trade at a high multiple of projected sales and the company is burning cash, increasing the risk of dilution.

Market Competition

There is skepticism about SENS's ability to gain traction in the CGM market against established competitors, despite the 365-day indication.

Regulatory and Commercial Risks

Risks to our investment thesis include regulatory requirements for additional clinical studies and a commercialization strategy dependent on partner ADC’s success.

Senseonics Holdings Business Overview & Revenue Model

Company Description

Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. The company's products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management for a period of up to six months. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. The company has a collaboration agreement with the University Hospitals Accountable Care Organization. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

How the Company Makes Money

Senseonics Holdings generates revenue primarily through the sale of its Eversense CGM system and related products. The company's revenue model involves direct sales to healthcare providers and distribution partnerships that facilitate the availability of its CGM systems in various markets. Key revenue streams include the initial purchase of the CGM system components and ongoing sales of consumables like sensors and transmitters required for continuous monitoring. Significant partnerships with healthcare providers, distribution partners, and insurers also contribute to its earnings by expanding market reach and facilitating reimbursement processes for patients.

Senseonics Holdings Financial Statement Overview

Summary

Senseonics Holdings faces significant financial challenges, including continuous losses and high leverage. While revenue shows slight growth, profitability remains a major concern with negative margins across the board. The balance sheet's negative equity and high debt levels indicate financial instability, and the cash flow statement reflects ongoing liquidity issues. The company must focus on improving operational efficiency and financial health to enhance its financial standing.

Income Statement

Senseonics Holdings has shown minimal revenue growth with a slight increase in total revenue from $22.39M in 2023 to $22.47M TTM. However, profitability metrics are concerning: Gross Profit Margin is low at 2.37%, and both EBIT and EBITDA margins are negative, indicating the company is operating at a significant loss. The Net Profit Margin is also negative, reflecting ongoing challenges in achieving profitability.

Balance Sheet

The company has a notably high Debt-to-Equity ratio due to negative equity, suggesting financial instability. The Return on Equity is not applicable due to negative equity. Additionally, the equity ratio is inverted due to negative stockholders' equity, highlighting potential financial distress. The balance sheet reveals a capital structure heavily reliant on debt.

Cash Flow

Operating cash flow remains negative, but there is a slight improvement in free cash flow from -$70.51M in 2023 to -$62.70M TTM. Operating Cash Flow to Net Income Ratio is not favorable at 0.77, indicating cash flow issues. However, financing activities have provided some cash influx, albeit this may not be sustainable long-term.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
22.47M	22.39M	16.39M	13.68M	4.95M	21.30M
	Gross Profit
533.00K	3.09M	2.73M	-811.00K	-17.37M	-19.45M
	EBIT
-74.84M	-75.60M	-68.63M	-57.18M	-79.13M	-130.66M
	EBITDA
-69.91M	-48.01M	161.81M	-284.51M	-157.86M	-99.41M
	Net Income Common Stockholders
-78.62M	-60.39M	142.12M	-317.78M	-191.02M	-126.23M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
74.60M	109.46M	144.01M	129.91M	18.00M	95.94M
	Total Assets
100.44M	138.22M	177.67M	198.93M	35.92M	132.60M
	Total Debt
60.63M	47.78M	74.65M	63.30M	62.70M	119.22M
	Net Debt
-13.97M	-27.93M	38.86M	29.84M	44.69M	23.29M
	Total Liabilities
116.99M	64.77M	180.25M	384.46M	180.00M	141.45M
	Stockholders Equity
-16.55M	73.45M	-2.58M	-185.53M	-144.08M	-8.85M
Cash Flow		Free Cash Flow
-62.70M	-70.51M	-66.62M	-56.29M	-67.60M	-137.09M
	Operating Cash Flow
-60.47M	-70.16M	-66.31M	-56.08M	-67.42M	-136.05M
	Investing Cash Flow
32.84M	89.71M	26.88M	-148.75M	-181.00K	-1.04M
	Financing Cash Flow
26.83M	20.37M	41.76M	220.08M	-10.13M	96.24M

Senseonics Holdings Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.50
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SENS, the sentiment is Negative. The current price of 0.5 is below the 20-day moving average (MA) of 0.62, below the 50-day MA of 0.64, and below the 200-day MA of 0.55, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 34.01 is Neutral, neither overbought nor oversold. The STOCH value of 6.87 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SENS.

Senseonics Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DXCM	81 Outperform	$33.26B	63.68	23.72%	―	9.11%	-17.87%
LIVN	63 Neutral	$2.28B	30.62	-19.69%	―	7.97%	-592.40%
OM	57 Neutral	$317.74M	―	-86.53%	―	-7.84%	42.34%
TNDM	55 Neutral	$1.38B	―	-92.31%	―	27.65%	-28.22%
Sector *	53 Neutral	$5.14B	3.03	-43.89%	2.83%	16.75%	-0.06%
SENS	50 Neutral	$380.69M	―	-161.19%	―	1.64%	16.02%
NNOX	50 Neutral	$327.10M	―	-30.11%	―	15.32%	15.73%

Senseonics Holdings Corporate Events

Senseonics Holdings Approves Director Elections and Proposals

At the Annual Meeting on May 21, 2025, Senseonics Holdings‘ stockholders voted on three proposals. The election of four directors was approved, with all nominees elected to serve until the 2028 annual meeting. Additionally, the stockholders approved the compensation for the company’s named executive officers and ratified the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (SENS) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Senseonics Holdings stock, see the SENS Stock Forecast page.

Senseonics Holdings Announces Major Stock Offering Agreement

On May 15, 2025, Senseonics Holdings, Inc. announced an underwriting agreement with TD Securities and Barclays Capital to issue and sell 100,000,000 shares of common stock at $0.50 per share, with an option for underwriters to purchase an additional 15,000,000 shares. The expected net proceeds of approximately $45.4 million, or $52.45 million if the option is exercised, will fund the launch of Eversense 365, development of pipeline products, and general corporate purposes. The offering is part of a shelf registration and includes a concurrent private placement with Abbott Laboratories for up to $25 million. The closing is expected on May 19, 2025, subject to customary conditions.

The most recent analyst rating on (SENS) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Senseonics Holdings stock, see the SENS Stock Forecast page.

Senseonics Holdings Enters Agreement with Abbott Laboratories

On May 15, 2025, Senseonics Holdings entered into a securities purchase agreement with Abbott Laboratories to sell up to $25 million of its common stock in a private placement, contingent upon the closing of a proposed public offering. This strategic move includes granting Abbott certain negotiation rights for potential future transactions, which could impact the company’s operational and market strategies. The agreement reflects Senseonics’ efforts to strengthen its financial position and explore strategic opportunities, potentially affecting stakeholders and the company’s industry positioning.

The most recent analyst rating on (SENS) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Senseonics Holdings stock, see the SENS Stock Forecast page.